The FDA has approved a new triple-drug antibiotic from Merck & Co, but the company and regulator have cautioned it should only be prescribed for last-ditch use. Recarbrio – which based on ...

The German drugmaker confirmed acquisition talks, but cautioned a deal may not materialize. Elsewhere, Biohaven got priority ...

Merck plans to stop a late-stage study testing its drug to treat pulmonary arterial hypertension (PAH) ahead of time based on ...

(Corrects third to last paragraph to say "the erosion from LOEs (loss of exclusivity)", not "from LOEs (levels of evidence)") ...

Report with market evolution powered by AI - The global antibiotics market size is estimated to grow by USD 18.22 billion ...

Merck MRK has decided to stop the phase III HYPERION study early. The study evaluates MRK’s pulmonary arterial hypertension (PAH) drug, Winrevair (sotatercept), for a more advanced version of ...

Its monotherapy drug that is used to treat desmoid tumors has been approved in the United States. A transaction for Springworks would rank as one of the biggest pharma deals for Merck in recent ...

indicates confidence in the drug’s efficacy but still requires further data presentation for comprehensive evaluation. While the trial’s early success and Merck’s increased sales guidance ...

Jan 24 (Reuters) - Merck (MRK.N), opens new tab and Japan-based Eisai (4523.T), opens new tab said on Friday a combination of their therapies failed to extend the lives of patients with a type of ...

Merck CEO Rob Davis told CNBC's Jim Cramer that there's more to the pharmaceutical giant than its lucrative cancer drug, Keytruda, and he described other ventures in its portfolio. "Keytruda has ...